- Home
- GNPX vs SGD Comparison
GNPX vs SGD Comparison
Compare GNPX & SGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- SGD
- Stock Information
- Founded
- GNPX 2009
- SGD 2021
- Country
- GNPX United States
- SGD United States
- Employees
- GNPX N/A
- SGD N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- SGD
- Sector
- GNPX Health Care
- SGD
- Exchange
- GNPX Nasdaq
- SGD Nasdaq
- Market Cap
- GNPX 5.5M
- SGD 4.4M
- IPO Year
- GNPX 2018
- SGD N/A
- Fundamental
- Price
- GNPX $0.25
- SGD $1.32
- Analyst Decision
- GNPX
- SGD
- Analyst Count
- GNPX 0
- SGD 0
- Target Price
- GNPX N/A
- SGD N/A
- AVG Volume (30 Days)
- GNPX 24.1M
- SGD 342.8K
- Earning Date
- GNPX 11-12-2025
- SGD 08-15-2025
- Dividend Yield
- GNPX N/A
- SGD N/A
- EPS Growth
- GNPX N/A
- SGD N/A
- EPS
- GNPX N/A
- SGD N/A
- Revenue
- GNPX N/A
- SGD $1,536,255.00
- Revenue This Year
- GNPX N/A
- SGD N/A
- Revenue Next Year
- GNPX N/A
- SGD N/A
- P/E Ratio
- GNPX N/A
- SGD N/A
- Revenue Growth
- GNPX N/A
- SGD 1570.24
- 52 Week Low
- GNPX $0.14
- SGD $0.65
- 52 Week High
- GNPX $3.97
- SGD $6.25
- Technical
- Relative Strength Index (RSI)
- GNPX 55.11
- SGD 54.54
- Support Level
- GNPX $0.22
- SGD $1.02
- Resistance Level
- GNPX $0.32
- SGD $1.39
- Average True Range (ATR)
- GNPX 0.05
- SGD 0.15
- MACD
- GNPX 0.01
- SGD 0.01
- Stochastic Oscillator
- GNPX 39.89
- SGD 50.53
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.